Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03913039 · ClinicalTrials.gov registry record
Reduction of Prostate Biopsy Morbidity
A clinical trial of Prostate Cancer, sponsored by Maimonides Medical Center.
- Completed
- Registry status
- 157
- Enrollment target
- 1
- Study location
NCT03913039: Completed study of Prostate Cancer, sponsored by Maimonides Medical Center.
NCT03913039 is a study of Prostate Cancer that has completed, run by Maimonides Medical Center. The registered enrollment target is 157 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03913039, a study of Prostate Cancer, has completed, sponsored by Maimonides Medical Center.
- COMPLETED
- Registry status
- 157 participants
- Enrollment target
- 1
- Study location
Study Summary
Prostate biopsy is typically performed via either the transrectal or transperineal approach. This study is a case-control study being done to determine if a novel prostate biopsy protocol incorporating a transperineal approach, rectal swab to detect resistant bacteria and broad antibiotic prophylaxis will reduce infectious complications and hospital readmission compared to current biopsy practices.
Primary Outcome
1\. Rate of any clinically significant post-biopsy complications including infectious complications and hospital readmissions within 30 days.
Conditions Studied
Interventions
- PROCEDURE Transperineal biopsy Protocol
Study Locations (1)
New York
- Maimonides Medical Center - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2021-12-31 |
What the finished NCT03913039 record still lists
NCT03913039 is an observational study that tracks outcomes without assigning an intervention. The registered 157 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Transperineal biopsy Protocol is the first listed.
NCT03913039 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03913039 about?
NCT03913039 is a clinical study titled "Reduction of Prostate Biopsy Morbidity". Prostate biopsy is typically performed via either the transrectal or transperineal approach. This study is a case-control study being done to determine if a novel prostate biopsy protocol incorporating a transperineal approach, rectal swab to detect resistant bacteria and broad antibiotic prophylaxi...
What is the current status of trial NCT03913039?
This trial is currently completed. The enrollment target is 157 participants. The study started on 2019-05-01. Estimated completion is 2021-12-31.
What conditions does trial NCT03913039 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT03913039?
The interventions under investigation include: Transperineal biopsy Protocol (PROCEDURE).
Who is sponsoring clinical trial NCT03913039?
This trial is sponsored by Maimonides Medical Center, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03913039 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03913039's enrollment target sits among peer trials
157 256th of 735 higher than 480 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05052541 · 157 participants · Phase 3
Safety and Efficacy of Oral Cannabis in Chronic Spine Pain
- NCT05076942 · 157 participants · Phase 2
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
- NCT06396598 · 157 participants · NA
Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer
- NCT06655246 · 157 participants · Phase 1
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI